Theradiag Opens a New Site in Tours
24 Septembre 2020 - 8:00AM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER,
eligible for the French PEA-PME personal equity plan), a
company specializing in in vitro diagnostics and theranostics, has
opened a new site in Tours, France.
In July, Theradiag announced a partnership with the University
of Tours: an exclusive licensing contract for making Covid-19 viral
proteins, plus a global collaboration agreement. As part of this
alliance, Theradiag wanted a local presence in France’s Centre-Val
de Loire region and has now, therefore, set up a secondary site in
Tours. This site will strengthen the existing collaboration and
allow to support developments planned alongside the University of
Tours and the local tech and economic environment, including a
number of Theradiag R&D projects. It will operate hand in hand
with the Company’s existing infrastructure and teams in the
Croissy-Beaubourg headquarters.
The different entities’ joint efforts will help Theradiag
provide new sources of raw materials and explore new business
opportunities such as bioproduction. At first, the Start’inbox
incubator will host the new operation, to which staff will be added
as business develops.
Theradiag CEO Bertrand de Castelnau said: “Theradiag is
looking to the future on several strategic fronts. We are delighted
to announce this new Tours site as it will help us make headway and
expand in the monitoring of biotherapies. The academic environment
in Tours is conducive to our work, with committed teams and reputed
biodrug specialists. The new site will be structuring in our
operations and create working conditions that will encourage
further teamwork and innovation. This will help develop monoclonal
antibodies, amongst other topics.”
***
Upcoming financial conference attended by Theradiag:
- October 1, 2020: Digital Portzamparc BNP Paribas
Healthcare/Biotech Seminar
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years. Theradiag
pioneered “theranostics” testing (combining therapy with
diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée‑, near Paris, has
operations in over 70 countries and employs over 60 people. In
2019, the Company posted revenue of €9.6 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005639/en/
Theradiag investor and media contacts: Theradiag
Bertrand de Castelnau CEO/Managing Director Tel.: +33 (0)1
64 62 10 12 contact@theradiag.com
NewCap Financial Communications &
Investor Relations Sandrine Boussard-Gallien Quentin
Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas
Mérigeau Tel.: +33 (0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theradiag (EU:ALTER)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024